Key result
The provided text contains only journal masthead information and does not include the study data or results.
Why the study?
Is hyperprolactinemia associated with enhanced platelet activation in ischemic stroke, and how do antiplatelet agents affect this pathway?
Population
116 patients, comprising 36 patients with ischemic stroke or transient ischemic attack, and 80 patients with…
Design
Cross-sectional
Authors
Loading...
Hyperprolactinemia may link to ischemic stroke via platelet activation; leaves open whether prolactin targeting or clopidogrel preference improves outcomes.
Is hyperprolactinemia associated with enhanced platelet activation in ischemic stroke, and how do antiplatelet agents affect this pathway?
Hyperprolactinemia may be a novel risk factor for ischemic stroke by enhancing platelet reactivity, an effect that is inhibited by clopidogrel but not aspirin in vitro.
Lohmann et al. (2006) studied ischemic stroke. prolactin was evaluated. The provided text contains only journal masthead information and does not include the study data or results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: